Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study

Hedy L. Kindler(University of Chicago), Tatsuya Ioka(Osaka Medical Center for Cancer and Cardiovascular Diseases), D. J. Richel(University of Amsterdam), Jaafar Bennouna(Centre Hospitalier René-Dubos), Richard Létourneau(Centre Hospitalier de l’Université de Montréal), Takuji Okusaka(Tokyo National Hospital), Akihiro Funakoshi(National Hospital Organization Kyushu Cancer Center), Junji Furuse(National Cancer Center Hospital East), Young Suk Park(Samsung Medical Center), Shinichi Ohkawa(Kanagawa Cancer Center), Gregory M. Springett(Moffitt Cancer Center), Harpreet Wasan(Hammersmith Hospital), Peter C. Trask(Pfizer (United States)), Paul Bycott(Pfizer (United States)), Alejandro D. Ricart(Pfizer (United States)), Sinil Kim(Pfizer (United States)), Eric Van Cutsem
The Lancet Oncology
February 8, 2011
Cited by 396

Abstract


Related Papers

No related papers found

Powered by citation graph analysis